hand for the study of other sorts of disease in the mass. The latest issue of the British Medical Bulletin' shows how diverse these researches have become.
With Professor E. D. Acheson as scientific editor the B.M.B. provides a series of authoritative reviews of some of the more important work being carried on at present in the epidemiological study of non-communicable diseases. That this study is not simply one for specialists is evident from the fruitful discoveries that individuals have sometimes made from an initially limited range of observations. Examples in our time are the late Sir Norman Gregg's connexion of congenital defects in babies with outbreaks of rubella, Mr. D. P. Burkitt's identification of a type of lymphoma with a special geographical distribution, and Dr. W. Lenz's In the study of the effects of industrial products and their processes on health the epidemiological approach has been particularly rewarding, for it is often possible to say with some precision which workers in a factory or whole industry have been exposed to a particular agent and which have not. Notable contributions have thus been made to our knowledge of pneumoconiosis and asbestos cancer, to name two diseases discussed here by Dr. S. Rae and by Dr. J. C. Wagner and his colleagues. Other respiratory diseases are the subject of papers by Dr. J. R. T. Colley and by Professor D. D. Reid and Dr. C. M. Fletcher, and they complement the report issued by the Royal College of Physicians of London2 3 this month on that exceedingly potent cause of respiratory disease, tobacco smoking. This too has given rise to some of the classic epidemiological investigations into non -communicable diseases, and incidentally presented in its sharpest form the question that every epidemiological study poses sooner or later: Does the correlation in this particular study mean causation? The evidence that tobacco smoking increases the likelihood of a person's contracting one of the diseases known to be associated with the practice is so great that the word "causation" is now unashamedly pronounced in this context. But that was hardly possible for some years after the first statistical papers appeared in 1950,4 5 and the authors of them long set an example in cautious interpretation that more impatient spirits sometimes found irksome.
Ifthe correlation-causation duality is a troublesome problem at the heart of every epidemiological investigation, another pitfall lies in the investigator's path at its beginning. That is the accuracy of the observations by which the data are obtained. The data may be industriously gathered, precisely analysed, and cautiously interpreted, yet be based on faulty observations. Risk of this needs to be specially guarded against when doctors not specially trained in research collect data, whether in hospital or general practice, for analysis by another person, or when an investigator obtains his information from patients through the intermediary ofnon-medical interviewers. In 
Long-acting Phenothiazines in Schizophrenia
Schizophrenics make up a large proportion of the patients in any mental hospital-not because the illness is so common, but because therapeutic failure leads to progressive deterioration. For this reason every effort must be made to cure the patient in the first attack as subsequent attacks are more difficult to treat. Unfortunately many patients cannot be cured, and then the aim must be to maintain as high a level of improvement as possible so that they can live outside hospital and lead an active life. The mainstays of therapy are the phenothiazine drugs, but ensuring that patients take their medication regularly is difficult. Apart from the lack of insight that is characteristic of any psychotic disorder, the patient and his friends may not realize the importance of continuing to take the drugs once they are better. Furthermore, stopping phenothiazines for a few days will not lead to an immediate relapse and may induce a false optimism. Thus up to 40% of schizophrenic outpatients do not take their tablets as prescribed,' and one in five inpatients do not take the tablets given them by the nursing staff." Nevertheless, relapses in schizophrenic patients are frequently directly related to stopping medication, particularly in patients whose symptoms have not completely cleared up. ' ' It is, therefore, not surprising that the long-acting preparations of fluphenazine have aroused such interest among psychiatrists. These preparations have the same clinical efficacy as the oral preparations when taken regularly,4 and their sole advantage is that they can be given by injection at one-to four-weekly intervals. The two preparations available at present are fluphenazine enanthate and fluphenazine decanoate; the latter is longer acting and probably has less tendency to produce extrapyramidal symptoms.5 Other preparations, such as fluspirilene and a derivative of pipothiazine, are on trial on the Continent.
Many centres have developed special outpatient clinics for patients on regular injections, and follow up patients energetically if they fail to attend. The increased frequency of attendances for injections and the attention and enthusiasm which new treatments always inspire would be expected to improve the results of fluphenazine therapy compared with those using the older drugs. No double-blind controlled investigations of long-acting fluphenazines have been reported, doubtless because of the ethical difficulties of giving regular injections of a placebo to the controls. Nevertheless, the claims that hospital admissions have been reduced by over half, '" or that patients have shown remarkable improvement when transferred from orthodox medication,9 are striking, and it seems reasonable to attribute much of the improvement to these long-acting preparations.
The side effects of the long-acting preparations are similar to those of oral fluphenazine and other piperazine derivatives. The most important are the extrapyramidal features, especially the dystonic reactions, which may be very frightening. As always these effects are related to age and dose, and some patients appear particularly sensitive. Nevertheless, these effects seem to be especially common in the early days of treatment with the long-acting fluphenazines after which they gradually decrease.'0 11 Hence the dosage should be increased very gradually, and most psychiatrists prescribe oral antiparkinsonian agents as a routine, even though there is always the problem of getting the patient to take them regularly. Possibly depression is particularly common with the longacting fluphenazines," though it is difficult to understand why the long-acting preparations should be more likely to cause this than the same drug given orally. Nevertheless, depression is a common feature of schizophrenia, and it is important to look out for it in all patients under treatment.
